Fig. 3. Neutralizing activity of mRNA vaccinee sera (pre- and post-booster) against live SARS-CoV-2 viruses.

Each dot represents the neutralizing titer (FRNT₅₀) of an individual serum sample against a specific SARS-CoV-2 virus, which is labeled on the X-axis. Different colors represent the progenitor virus or different variants and subvariants. The geometric mean FRNT₅₀ titers are represented in the graph as bars on top of the dots with geometric standard deviation. The geometric mean FRNT₅₀ titers (avg. titer) and average fold changes relative to reference virus 614D (set as 1-fold) are shown on the top of the graph. Dashed line represents the limit of quantitation (LOQ). For statistical analysis, a two-tailed Wilcoxon matched-pairs signed-rank test was performed by comparing each variant with 614D. Test statistics and P value are summarized in Supplementary Table 2. Source data are provided as a Source Data file. a 614D, Beta, and Omicron subvariants BA.1 and BA.2 reporter viruses were tested. N = 20 biologically independent pre-booster sera (6–7 months post-second dose). The average fold changes of all variants differ significantly (P < 0.0001) from 614D. LOQ = 5. b 614D, Beta and Omicron subvariants BA.1 and BA.2 reporter viruses were tested. N = 20 biologically independent post-booster sera (2–6 weeks post-third dose). The average fold changes of all viruses differ significantly (P < 0.0001) from 614D. LOQ = 10. c 614D and Omicron subvariants BA.1, BA.1.1, and BA.2 isolated from clinical specimens were tested. N = 20–25 biologically independent post-booster sera examined over four viruses. The average fold changes of all viruses differ significantly (P < 0.0001) from 614D. LOQ = 10.